| Product Dating |
McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 30 days | McKesson Acceptable Dating: we will ship >= 60 days |
| Features and Benefits |
- The Lyra Parainfluenza Virus Assay is a Real-Time PCR assay for the qualitative detection and identification of human parainfluenza virus types 1, 2 and 3 viral RNA from nasal and nasopharyngeal swab specimens from symptomatic patients
- Results in less than 75 minutes after extraction
- Simplified and uniform workflow with standard pipetting volumes
- The Lyra Parainfluenza Virus Assay has a convenient, one-step reagent set up performed at room temperature on the bench top, without the need for ice or other cooling accessories
- Kit includes vials of 12 x 8 Master Mix, Rehydration Solution and liquid Process Controls
|
- Xpert® Xpress Strep A is a qualitative real-time PCR test providing accurate detection of Group A Streptococcus in as soon as 18 minutes
- Xpert® Xpress Strep A provides medically actionable and timely information to clinicians to support improved patient management and antibiotic stewardship
- For In Vitro Diagnostic Use
|
- 90 minute detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG)
|
- Qualitative detection of Neisseria gonorrhoeae DNA in clinician-collected female endocervical and male urethral swab specimens, patient-collected vaginal swab specimens (in a clinical setting), and male and female urine specimens
|
- cobas® SARS-CoV-2 & Influenza A/B nucleic acid test for use on the cobas® liat analyzer has successfully completed its transition from Emergency Use Authorization (EUA) product to 510(k) cleared product
- Product ships from McKesson with minimum 30 days dating
- The cobas® SARS-CoV-2 & Influenza A/B Nucleic acid test for use on the cobas® Liat® System (cobas® SARS-CoV-2 & Influenza A/B) is an automated rapid multiplex real-time, reverse transcriptase polymerase chain reaction (RT-PCR) test intended for the simultaneous qualitative detection and differentiation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A, and influenza B virus nucleic acid in nasopharyngeal swab (NPS) and anterior nasal swab (ANS) specimens from individuals with signs and symptoms of respiratory tract infection
- cobas® SARS-CoV-2 & Influenza A/B is intended for use as an aid in the differential diagnosis of SARS-CoV-2, influenza A, and/or influenza B infection if used in conjunction with other clinical and epidemiological information, and laboratory findings
- The new cobas SARS-CoV-2 & Influenza A/B test analyzes nucleic acids from nasopharyngeal and nasal swab samples and self-collected nasal swabs (collected in a healthcare setting with instruction by a healthcare provider) to enable frontline healthcare workers to quickly identify and differentiate these similarly presenting infections
- cobas® SARS-CoV-2 & Influenza A/B is intended for use by health professionals or trained operators who are proficient in using the cobas® Liat System
- The cobas® SARS-CoV-2 & Influenza A/B Nucleic acid test for use on the cobas® Liat® System (cobas® SARS-CoV-2 & Influenza A/B) is an automated multiplex real-time RT-PCR assay intended for the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B virus RNA
- Kit includes: 20 tests, 2 cobas® transfer pipette packs (12 pipettes/pack - P/N 9329676001), 1 package insert barcode card, cobas Liat Internal Process Control, Proteinase K, cobas Liat Magnetic Glass Particles, Lysis buffer, wash buffer, Elution buffer, A/B Master Mix 1, A/B Master Mix 2, A/B Master Mix 3
|
